Novo Nordisk CEO: Not exactly clear yet what Medicare price negotiations will do for financials

Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Squawk on the Street' to discuss what's known about the White House's negotiations for specific drug prices, long-term worries about suppressed R&D activity, and much more.